Anti-NMDA receptor encephalitis secondary prevention: Difference between revisions
| Line 23: | Line 23: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
<ref name="pmid24360484">{{cite journal| author=Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F | display-authors=etal| title=Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. | journal=Lancet Neurol | year= 2014 | volume= 13 | issue= 2 | pages= 167-77 | pmid=24360484 | doi=10.1016/S1474-4422(13)70282-5 | pmc=4006368 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24360484 }} </ref> | <ref name="pmid24360484">{{cite journal| author=Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F | display-authors=etal| title=Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. | journal=Lancet Neurol | year= 2014 | volume= 13 | issue= 2 | pages= 167-77 | pmid=24360484 | doi=10.1016/S1474-4422(13)70282-5 | pmc=4006368 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24360484 }} </ref> | ||
<ref name="pmid21933952">{{cite journal| author=Finke C, Kopp UA, Prüss H, Dalmau J, Wandinger KP, Ploner CJ| title=Cognitive deficits following anti-NMDA receptor encephalitis. | journal=J Neurol Neurosurg Psychiatry | year= 2012 | volume= 83 | issue= 2 | pages= 195-8 | pmid=21933952 | doi=10.1136/jnnp-2011-300411 | pmc=3718487 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21933952 }} </ref> | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 17:36, 13 May 2023
|
Anti-NMDA receptor encephalitis Microchapters |
|
Differentiating Anti-NMDA receptor encephalitis from Other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Anti-NMDA receptor encephalitis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Anti-NMDA receptor encephalitis secondary prevention |
|
Anti-NMDA receptor encephalitis secondary prevention in the news |
|
Blogs on Anti-NMDA receptor encephalitis secondary prevention |
|
Directions to Hospitals Treating Anti-NMDA receptor encephalitis |
|
Risk calculators and risk factors for Anti-NMDA receptor encephalitis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] AE Dheeraj Makkar, M.D.[2]
Overview
Secondary prevention of anti-NMDA encephalitis involves strategies aimed at early detection, timely intervention, and management to prevent disease progression and complications. Since anti-NMDA encephalitis often presents with neuropsychiatric symptoms, prompt recognition and appropriate referral to specialized medical care are crucial.
Secondary Prevention
Secondary prevention measures include:
- 1. Education and Awareness: Increasing awareness among healthcare professionals, including neurologists, psychiatrists, and primary care providers, about the clinical presentation and diagnostic criteria of anti-NMDA encephalitis can facilitate early identification and intervention.
- 2. Diagnostic Workup: Implementing a standardized diagnostic workup, including brain imaging, electroencephalography (EEG), cerebrospinal fluid (CSF) analysis, and antibody testing, can aid in confirming the diagnosis and guiding appropriate treatment.
- 3. Timely Initiation of Treatment: Early initiation of immunotherapy, such as corticosteroids, immune plasmapheresis, intravenous immunoglobulins, and rituximab, has been associated with better outcomes and reduced morbidity and mortality. Prompt removal of the underlying tumor, if present, is also important.
- 4. Multidisciplinary Approach: Collaboration among neurologists, psychiatrists, immunologists, and other specialists is essential for a comprehensive evaluation, management, and follow-up care of patients with anti-NMDA encephalitis.
References
[1] [2] Template:WH Template:WS
- ↑ Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F; et al. (2014). "Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study". Lancet Neurol. 13 (2): 167–77. doi:10.1016/S1474-4422(13)70282-5. PMC 4006368. PMID 24360484.
- ↑ Finke C, Kopp UA, Prüss H, Dalmau J, Wandinger KP, Ploner CJ (2012). "Cognitive deficits following anti-NMDA receptor encephalitis". J Neurol Neurosurg Psychiatry. 83 (2): 195–8. doi:10.1136/jnnp-2011-300411. PMC 3718487. PMID 21933952.